Guidebook for Drug Regulatory Submissions


Book Description

Destined to become every regulatory director's essential desktop companion Professionals working to submit major documents to the Food and Drug Administration (FDA) are guaranteed to encounter numerous unexpected and daunting hurdles. Guidebook for Drug Regulatory Submissions offers a readable and clearly written road map for effective submission of documents for required regulatory reviews during drug development. Demystifying this complex, high-stakes process, author and nationally recognized drug regulation expert Sandy Weinberg presents professionals with authoritative tips, tools, and advice including suggestions for preparation, checklists for submission, an FDA evaluation tool for review, and copies of relevant FDA guidelines. As well, vital information is provided on the most common types of submissions, including: Meeting Requests Orphan Drug Applications Investigatory New Drug Applications (INDAs) New Drug Applications (NDAs) 505(b)2 NDAs Abbreviated New Drug Applications (ANDAs) Annual Report This reference also explores the pressures affecting the industry and the general public, as well as how these pressures will change the general nature and specific aspects of the submissions process over the near future. In addition, retired Canadian trade consul and regulatory consultant Carl Rockburne guest-authors a chapter comparing the FDA process to the four other major regulatory environments of Canada, the European Union, Japan, and Australia. Guidebook for Drug Regulatory Submissions is more than a useful guide it is an essential tool to be kept on the desk of every regulatory director, submissions manager, vice president of Regulatory Affairs, and Food and Drug Administration reviewer responsible for the process of drug regulatory submissions.




Guidebook for Drug Regulatory Submissions


Book Description

Destined to become every regulatory director's essential desktop companion Professionals working to submit major documents to the Food and Drug Administration (FDA) are guaranteed to encounter numerous unexpected and daunting hurdles. Guidebook for Drug Regulatory Submissions offers a readable and clearly written road map for effective submission of documents for required regulatory reviews during drug development. Demystifying this complex, high-stakes process, author and nationally recognized drug regulation expert Sandy Weinberg presents professionals with authoritative tips, tools, and advice including suggestions for preparation, checklists for submission, an FDA evaluation tool for review, and copies of relevant FDA guidelines. As well, vital information is provided on the most common types of submissions, including: Meeting Requests Orphan Drug Applications Investigatory New Drug Applications (INDAs) New Drug Applications (NDAs) 505(b)2 NDAs Abbreviated New Drug Applications (ANDAs) Annual Report This reference also explores the pressures affecting the industry and the general public, as well as how these pressures will change the general nature and specific aspects of the submissions process over the near future. In addition, retired Canadian trade consul and regulatory consultant Carl Rockburne guest-authors a chapter comparing the FDA process to the four other major regulatory environments of Canada, the European Union, Japan, and Australia. Guidebook for Drug Regulatory Submissions is more than a useful guide—it is an essential tool to be kept on the desk of every regulatory director, submissions manager, vice president of Regulatory Affairs, and Food and Drug Administration reviewer responsible for the process of drug regulatory submissions.




Cost-Contained Regulatory Compliance


Book Description

This book guides the reader through FDA regulation guidelines and outlines a comprehensive strategy for cost reduction in regulatory affairs and compliance. This book explains six strategies to cost-effectively comply with FDA regulations while maintaining product safety and improving public access through cost controls. It provides useful and practical guidance through industry case studies from pharmaceutical, biotech, and medical device industries.




Good Drug Regulatory Practices


Book Description

Good Drug Regulatory Practices offers a series of policies and procedures to assure quality and timely regulatory submissions to national regulatory agencies. This book begins with introductory chapters describing the need for policy documentation, and the philosophy underlying the policies, and presents policies and standards that can be used as presented or adapted to individual situations in your company.




FDA Regulatory Affairs


Book Description

Examines harmonization of the US Federal Food, Drug, and Cosmetic Act with international regulations as they apply to human drug and device development, research, manufacturing, and marketing. The Second Edition focuses on the new drug approval process, cGMPs, GCPs, quality system compliance, and corresponding documentation requirements. Written in




Guide for Drug Regulatory Submissions


Book Description

The high-stakes process of submitting drug documents and applications for regulatory review can be intimidating, particularly for the inexperienced regulatory professional charged with preparing a major regulatory submission. This book provides regulatory professionals with the key tools necessary to submit major documents to the United States Food and Drug Administration. The book consists of thirteen chapters, including an introductory and conclusion chapter and 11 units, each consisting of an introductory essay, submission checklist.




Guide to Drug Regulatory Affairs


Book Description

Z.T. basierend auf dem "Handbuch der EU-Zulassung". Buch und Online-Version (Firmenlizenz auf Anfrage).




International Clinical Trials


Book Description

Regulations and standards involving clinical trials vary from country to country based on different laws, cultures, and social structures. International Clinical Trials: A Guidebook to National Drug Laws succeeds in collecting current guidelines into a single source that allows regulatory bodies in the pharmaceutical industry to prepare product approval submissions and meet international standards for performing clinical trials. It covers regulations in 34 countries in Europe, Austral-Asia, Africa, North America, and South America. Authored by locally based experts that include government authorities, national Ethics Committee chairpersons, company regulatory affairs professionals, and independent consultants, this book provides the information necessary for performing clinical trials, from initiation to termination and reporting. It includes forms and excerpts from existing regulations and interprets processes as they relate to ICH GCP guidelines. While chapters are presented in a similar format, they differ in their content to reflect the differing requirements throughout the world. A cornerstone in this field, this book is indispensable to those who must understand and comply with the standards of biomedical research on human beings as the pharmaceutical industry and regulators work to establish a universal set of requirements for performing clinical trials.




International Clinical Trials


Book Description

Regulations and standards involving clinical trials vary from country to country based on different laws, cultures, and social structures. International Clinical Trials: A Guidebook to National Drug Laws succeeds in collecting current guidelines into a single source that allows regulatory bodies in the pharmaceutical industry to prepare product approval submissions and meet international standards for performing clinical trials. It covers regulations in 34 countries in Europe, Austral-Asia, Africa, North America, and South America. Authored by locally based experts that include government authorities, national Ethics Committee chairpersons, company regulatory affairs professionals, and independent consultants, this book provides the information necessary for performing clinical trials, from initiation to termination and reporting. It includes forms and excerpts from existing regulations and interprets processes as they relate to ICH GCP guidelines. While chapters are presented in a similar format, they differ in their content to reflect the differing requirements throughout the world. A cornerstone in this field, this book is indispensable to those who must understand and comply with the standards of biomedical research on human beings as the pharmaceutical industry and regulators work to establish a universal set of requirements for performing clinical trials.